DARA BioSciences, Inc.
(Public, NASDAQ:DARA) Watch this stockFind more results for
DARA
Advertisement
Events
Dec 1, 2009
Dara Biosciences at New York Society of Security Analysts Biotech & Specialty Pharmaceuticals Industry Conference
- 1:30PM EST -
Nov 3, 2009
Dara Biosciences at Cambridge Healthtech Institute Discovery on Target Conference
|
More events from AOL Finance »
|
Key stats and ratios
| Q2 (Jun '09) | 2008 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -126.48% | -181.73% |
| Return on average equity | - | -259.92% |
| Employees | 5 | - |
Address
8601 Six Forks Road, Suite 160,
Raleigh, NC 27615
United States - Map
+1-919-8725578 (Phone)
+1-919-8610239 (Fax)
Raleigh, NC 27615
United States - Map
+1-919-8725578 (Phone)
+1-919-8610239 (Fax)
Website links
Company website:
http://www.darabiosciences.com/
http://www.darabiosciences.com/
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
DARA BioSciences, Inc. discussions
View all discussions »Description
DARA BioSciences, Inc. (DARA), formerly Point therapeutics, Inc. is a development stage pharmaceutical company that acquires therapeutic molecules and medical technologies from third parties, and advances their clinical development for later sale to pharmaceutical and biotechnology companies. DARA focuses on two drug development programs: KRN5500 for neuropathic pain in cancer patients and DB959 for type 2 diabetes. On February 12, 2008, Point and DARA BioSciences, Inc. completed their merger transaction, in which DP Acquisition Corp. (a wholly owned subsidiary of Point) merged with and into DARA BioSciences, Inc.
Officers and directors
| Richard A. Franco Sr. | President, Chief Executive Officer, Director | |
| Ann A. Rosar | Chief Accounting Officer, Controller | |
| Haywood D. Cochrane Jr. | Director | |
| David J. Drutz M.D | Director | |
| Gail F. Lieberman | Director |